A Multimodal Therapeutic Nanoplatform Overcoming Tumor Hypoxia Heterogeneity for Improved Tumor Chemoradiotherapy
Authors:
- 16 June 2022
- journal article
- research article
- Published by Wiley in Advanced Functional Materials
- Vol. 32 (34)
Abstract
The hypoxic nature of solid tumors limits the efficacy of radiotherapy (RT) and leads to radiation resistance. Hypoxic radiosensitizers can enhance tumor radiosensitivity by mimicking the effects of oxygen, but their efficacy has been limited by the heterogeneous oxygen distribution in tumor tissue. Herein, a multimodal therapeutic nanoplatform fabricated by co‐encapsulation of chlorin e6 and tirapazamine (TPZ) with an amphiphilic polymeric conjugate of cisplatin (CDDP) and metronidazole is reported. This platform could kill the tumor periphery cells by the deeply penetrated oxygen‐consuming sonodynamic therapy and unify the heterogeneously hypoxic context simultaneously, which then actuate the release and activation of the loaded TPZ. TPZ could further sensitize RT along with CDDP and metronidazole residues under the resultant hypoxic condition, which significantly decreases the radiation dosage required to cause massive cell damage. Except for the significantly suppressed tumor growth and metastasis caused by the multimodal therapeutic nanoplatform, its hypoxia‐directed feature also endows it with excellent safety.Keywords
Funding Information
- National Natural Science Foundation of China (51973014)
- National Natural Science Foundation of China (21774008)
- National Natural Science Foundation of China (52033001)
- Fundamental Research Funds for the Central Universities (XK1701)
- Fundamental Research Funds for the Central Universities (XK1802‐8)
- Fundamental Research Funds for the Central Universities (BUCTRC201912)
This publication has 74 references indexed in Scilit:
- Pharmacokinetic study of a novel sonosensitizer chlorin‐e6 and its sonodynamic anti‐cancer activity in hepatoma‐22 tumor‐bearing miceBiopharmaceutics & Drug Disposition, 2011
- Guidelines for preclinical and early phase clinical assessment of novel radiosensitisersBritish Journal of Cancer, 2011
- Targeting hypoxia in cancer therapyNature Reviews Cancer, 2011
- Strategies to improve radiotherapy with targeted drugsNature Reviews Cancer, 2011
- In vitro and in vivo study of a nanoliposomal cisplatin as a radiosensitizerInternational Journal of Nanomedicine, 2011
- Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum(IV) WarheadsJournal of the American Chemical Society, 2009
- DNA Repair: Common Approaches to Fixing Double-Strand BreaksCurrent Biology, 2009
- Imagable 4T1 model for the study of late stage breast cancerBMC Cancer, 2008
- Hypoxia, DNA repair and genetic instabilityNature Reviews Cancer, 2008
- Clonogenic assay of cells in vitroNature Protocols, 2006